Recent developments in kidney cancer

Journal of the Canadian Urological Association

Volumn 5, Issue 3, 2011, Pages 195-203

  Leveridge, Michael J ^a   Jewett, Michael A S ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958089467     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.10148     Document Type: Review

References (91)

1. Canadian Cancer Society. Canadian Cancer Statistics 2010. Canadian Cancer Society; 2010.
2. Silver DA, Morash C, Brenner P, et al. Pathologic findings at the time of nephrectomy for renal mass. Ann Surg Oncol 1997;4:570-4.
3. Volpe A, Kachura JR, Geddie WR, et al. Techniques, safety and accuracy of sampling of renal tumours by fine needle aspiration and core biopsy. J Urol 2007;178:379-86.
4. Volpe A, Mattar K, Finelli A, et al. Contemporary results of percutaneous biopsy of 100 small renal masses: A single center experience. J Urol 2008;180:2333-7.
5. Lane BR, Samplaski MK, Herts BR, et al. Renal mass biopsy--a renaissance? J Urol 2008;179:20-7.
6. Laguna MP, Kummerlin I, Rioja J, et al. Biopsy of a renal mass: Where are we now? Curr Opin Urol 2009;19:447-53.
7. Edge SB, Byrd DR, Compton CC, et al., editors. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
8. Greene FL, Page DL, Fleming ID, et al., editors. AJCC Cancer Staging Manual. 6th ed. 6th ed. New York, NY: Lippincott Raven Publishers; 2002.
9. Ficarra V, Galfano A, Guille F, et al. A new staging system for locally advanced (pT3-4) renal cell carcinoma: A multicenter European study including 2,000 patients. J Urol 2007;178:418-24.
10. Ficarra V, Galfano A, Mancini M, et al. TNM staging system for renal-cell carcinoma: Current status and future perspectives. Lancet Oncol 2007;8:554-8.
11. Ficarra V, Novara G, Iafrate M, et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol 2007;51:722,9.
12. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol 2009;182:1271-9.
13. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard J, et al. Guidelines on renal cell carcinoma. European Association of Urology. http://www.uroweb.org/fileadmin/tx_eauguidelines/ 2009/Full/RCC.pdf. Accessed April 18, 2011.
14. Canadian Kidney Cancer Forum 2008. Management of kidney cancer: Canadian kidney cancer forum consensus statement. Can Urol Assoc J 2008;2:175-82.
15. Kassouf W, Siemens R, Morash C, et al. Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J 2009;3:73-6
16. Ng CS, Wood CG, Silverman PM, et al. Renal cell carcinoma: Diagnosis, staging, and surveillance. AJR Am J Roentgenol 2008;191:1220-32.
17. Silverman SG, Leyendecker JR, Amis ES Jr. What is the current role of CT urography and MR urography in the evaluation of the urinary tract? Radiology 2009;250:309-23.
18. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84.
19. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008;81:362-78.
20. Tubiana M. Computed tomography and radiation exposure. N Engl J Med 2008;358:850.
21. Agarwal R, Brunelli SM, Williams K, et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: A systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:856-63. Epub 2008 Oct 24.
22. Kim S, Naik M, Sigmund E, et al. Diffusion-weighted MR imaging of the kidneys and the urinary tract. Magn Reson Imaging Clin N Am 2008;16:585-96.
23. Kang DE, White RL Jr, Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004;171:1806-9.
24. Aide N, Cappele O, Bottet P, et al. Efficiency of [18F]FDG PET in characterizing renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003;30:1236-45.
25. Wu H, Yen R, Shen Y, et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas-a preliminary report. J Cancer Res Clin Oncol 2002;128:503-6.
26. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001;166:825-30.
27. Jadvar H, Kherbache HM, Pinski JK, et al. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 2003;60:395-400.
28. Dilhuydy MS, Durieux A, Pariente A, et al. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation. Oncology 2006;70:339-44.
29. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009;103:615-9.
30. Ascenti G, Mazziotti S, Zimbaro G, et al. Complex cystic renal masses: Characterization with contrastenhanced US. Radiology 2007;243:158-65.
31. Fan L, Lianfang D, Jinfang X, et al. Diagnostic efficacy of contrast-enhanced ultrasonography in solid renal parenchymal lesions with maximum diameters of 5 cm. J Ultrasound Med 2008;27:875-85.
32. Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:1066-70.
33. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008;179:468-71.
34. Zorn KC, Gong EM, Orvieto MA, et al. Comparison of laparoscopic radical and partial nephrectomy: Effects on long-term serum creatinine. Urology 2007;69:1035-40.
35. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: A retrospective cohort study. Lancet Oncol 2006;7:735-40.
36. Sorbellini M, Kattan MW, Snyder ME, et al. Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. J Urol 2006;176:472-6.
37. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
38. Lane BR, Babineau DC, Poggio ED, et al. Factors predicting renal functional outcome after partial nephrectomy. J Urol 2008;180:2363-8.
39. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumours--is there a difference in mortality and cardiovascular outcomes? J Urol 2009;181:55-61.
40. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med 2009;360:459-69.
41. Bijol V, Mendez GP, Hurwitz S, et al. Evaluation of the nonneoplastic pathology in tumour nephrectomy specimens: Predicting the risk of progressive renal failure. Am J Surg Pathol 2006;30:575-84.
42. Gervais DA, McGovern FJ, Arellano RS, et al. Radiofrequency ablation of renal cell carcinoma: Part 1, indications, results, and role in patient management over a 6-year period and ablation of 100 tumours. AJR Am J Roentgenol 2005;185:64-71.
43. Park S, Anderson JK, Matsumoto ED, et al. Radiofrequency ablation of renal tumours: Intermediate-term results. J Endourol 2006;20:569-73.
44. Zagoria RJ, Traver MA, Werle DM, et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol 2007;189:429-36.
45. Levinson AW, Su LM, Agarwal D, et al. Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol 2008;180:499-504.
46. Wyler SF, Sulser T, Ruszat R, et al. Intermediate-term results of retroperitoneoscopy-assisted cryotherapy for small renal tumours using multiple ultrathin cryoprobes. Eur Urol 2007;51:971-9.
47. Weld KJ, Figenshau RS, Venkatesh R, et al. Laparoscopic cryoablation for small renal masses: Three-year follow-up. Urology 2007;69:448-51.
48. Lehman DS, Hruby GW, Phillips CK, et al. First prize (tie): Laparoscopic renal cryoablation: Efficacy and complications for larger renal masses. J Endourol 2008;22:1123-7.
49. Aron M, Kazumi K, Haber G, et al. Laparoscopic renal cryoablation long-term oncologic outcomes with minimum 5-year follow-up. J Urol 2008;179(4S):209-10.
50. Atwell TD, Farrell MA, Leibovich BC, et al. Percutaneous renal cryoablation: Experience treating 115 tumours. J Urol 2008;179:2136-40.
51. Caviezel A, Terraz S, Schmidlin F, et al. Percutaneous cryoablation of small kidney tumours under magnetic resonance imaging guidance: Medium-term follow-up. Scand J Urol Nephrol 2008;42:412-6.
52. Finley DS, Beck S, Box G, et al. Percutaneous and laparoscopic cryoablation of small renal masses. J Urol 2008;180:492-8.
53. Leveridge MJ, Mattar K, Kachura J, et al. Assessing outcomes in probe ablative therapies for small renal masses. J Endourol 2010;24:759-64.
54. Cadeddu JA, Raman JD. Renal tumour ablation is a function of patient selection and technique--not the ablation technology. Cancer 2008;113:2623-6.
55. Chawla SN, Crispen PL, Hanlon AL, et al. The natural history of observed enhancing renal masses: Metaanalysis and review of the world literature. J Urol 2006;175:425-31.
56. Michaels MJ, Rhee HK, Mourtzinos AP, et al. Incomplete renal tumour destruction using radio frequency interstitial ablation. J Urol 2002;168:2406-9.
57. Rendon RA, Kachura JR, Sweet JM, et al. The uncertainty of radio frequency treatment of renal cell carcinoma: Findings at immediate and delayed nephrectomy. J Urol 2002;167:1587-92.
58. Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumours. J Urol 2008;179(4):1277,81.
59. Raman JD, Stern JM, Zeltser I, et al. Absence of viable renal carcinoma in biopsies performed more than 1 year following radio frequency ablation confirms reliability of axial imaging. J Urol 2008;179:2142-5.
60. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
61. Canadian Kidney Cancer Forum 2009. Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Update. Can Urol Assoc J 2009;3:200-4.
62. Tsui KH, Shvarts O, Barbaric Z, et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol 2000;163:437-41.
63. O'Malley RL, Godoy G, Kanofsky JA, et al. The necessity of adrenalectomy at the time of radical nephrectomy: A systematic review. J Urol 2009;181:2009-17. Epub 2009 Mar 14.
64. Lane BR, Tiong HY, Campbell SC, et al. Management of the adrenal gland during partial nephrectomy. J Urol 2009;181:2430-6.
65. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: Final results of european organization for research and treatment of cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:28-34. Epub 2008 Oct 1.
66. Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: The pendulum swings back. Cancer J 2008;14:308-14.
67. Canfield SE, Kamat AM, Sanchez-Ortiz RF, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): The impact of aggressive surgical resection on patient outcome. J Urol 2006;175(3 Pt 1):864-9.
68. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: Role of lymph node dissection. J Urol 2003;169:2076-83.
69. Boorjian SA, Crispen PL, Lohse CM, et al. Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol 2008;180:99-103.
70. Haferkamp A, Bastian PJ, Jakobi H, et al. Renal cell carcinoma with tumour thrombus extension into the vena cava: Prospective long-term followup. J Urol 2007;177:1703-8.
71. Wagner B, Patard JJ, Mejean A, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol 2009;55:460. Epub 2008 Aug 5.
72. Granberg CF, Boorjian SA, Schaff HV, et al. Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumour thrombectomy facilitated by vascular bypass. Urology 2008;72:148-52.
73. Blute ML, Boorjian SA, Leibovich BC, et al. Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumour thrombectomy. J Urol 2007;178:440-5.
74. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumour stage, size, grade and necrosis: The SSIGN score. J Urol 2002;168:2395-400.
75. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63-7.
76. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005;173:48-51.
77. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-66.
78. Levy DA, Slaton JW, Swanson DA, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163-7.
79. Ljungberg B, Alamdari FI, Rasmuson T, et al. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999;84:405-11.
80. Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 2007;51:1490-500.
81. Stephenson AJ, Chetner MP, Rourke K, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 2004;172:58-62.
82. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
83. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
84. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
85. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-30.
86. Patard JJ. European association of urology guidelines for systemic therapy in metastatic renal cell carcinoma: What is recommended and why? Eur Urol Suppl 2008;7:46-54.
87. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
88. Mickisch GH, Garin A, van Poppel H, et al., European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 2001;358:966-70.
89. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
90. Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: Is it still imperative in the era of targeted therapy? Clin Cancer Res 2007;13(2 Pt 2):693s-6s.
91. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008;180:94-8.